← Leaderboards
Kelly C Goldsmith
Children'S Hosp Of Philadelphia
$1,560,816
Attributed
$2,317,031
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $576.7K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,317,031 · 3
By mechanism
R01$1,145,381 · 1
K08$804,600 · 1
R21$367,050 · 1
Top collaborators
- Kavita Dhodapkar2 shared
- H Trent Spencer2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Michael Chorny$5,184,479
- Robbie G. Majzner$6,350,674
Others in their field
Top investigators on “Chemotherapy”
- George R Seage · Abt Associates, Inc.$223,371,661
- Charles A Coltman · Southwest Oncology Group$170,244,220
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$154,566,243
- Philip J Disaia · University Of California Irvine$115,055,799
- Norman Wolmark · Nsabp Foundation, Inc.$106,367,723
Research focus
ChemotherapyNeuroblastomaIn VitroCellsTumorResistanceChildhood Solid NeoplasmRelapseMalignant NeoplasmsHigh RiskBaseReceptorCell LineResponseIn VivoMediatingSerumEnvironmentAffectApoptosisDeath DomainDesignChemosensitizationDisabled Persons
Grant awards (11)
Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastoma$568,722
R01 · FY2025 · CA · contact PI
Tumor and Host Immune signatures associated with health disparities in outcomes following GD2 immunotherapy in neuroblastoma$576,659
R01 · FY2024 · CA · contact PI
Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells$166,413
R21 · FY2019 · CA · contact PI
Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells$200,637
R21 · FY2018 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$139,320
K08 · FY2012 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$139,320
K08 · FY2011 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$139,320
K08 · FY2010 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$108,000
K08 · FY2009 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$104,490
K08 · FY2009 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$34,830
K08 · FY2009 · CA · contact PI
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma$139,320
K08 · FY2008 · CA · contact PI